Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 umbrella study of busorolimab-based neoadjuvant therapy for high-risk early triple-negative breast cancer
MOH_2025-01-14_013849Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in triple-negative breast cancer (TNBC) comparing Standard-of-care reference arm with Experimental busorolimab arm (2 arms). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
boserolimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2025-01-14_013849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-14_013849.